TScan Therapeutics (TCRX) Net Shares Issued and Repurchased (2021 - 2025)

TScan Therapeutics (TCRX) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $6.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased rose 78.41% year-over-year to $6.2 million in Q4 2025; TTM through Dec 2025 was $6.2 million, a 78.41% increase from a year earlier, with the FY2025 full-year figure at $6.2 million, up 78.41% from the prior year.
• Net Shares Issued and Repurchased was $6.2 million for Q4 2025 at TScan Therapeutics, up from $3.5 million in the prior quarter.
• Over five years, Net Shares Issued and Repurchased peaked at $8.5 million in Q4 2023 and troughed at $2.0 million in Q4 2021.
• A 5-year average of $4.6 million and a median of $3.5 million in 2024 frame the typical range for Net Shares Issued and Repurchased.
• Across the five-year window, Net Shares Issued and Repurchased jumped 229.45% in 2023 and plunged 59.02% in 2024, its largest moves.
• Over 5 years, Net Shares Issued and Repurchased stood at $2.0 million in 2021, then surged by 30.9% to $2.6 million in 2022, then jumped by 229.45% to $8.5 million in 2023, then tumbled by 59.02% to $3.5 million in 2024, then jumped by 78.41% to $6.2 million in 2025.
• The last three Net Shares Issued and Repurchased figures came in at $6.2 million (Q4 2025), $3.5 million (Q4 2024), and $8.5 million (Q4 2023), per Business Quant data.